Advanced Bladder Cancer VL

From Dismal to Promising: Discoveries Transforming Treatment Options for Advanced Urothelial Carcinoma - Shilpa Gupta

Details
Sam Chang welcomes Shilpa Gupta to discuss the evolving treatment paradigm for advanced urothelial carcinoma, focusing particularly on platinum eligibility for patients. Dr. Gupta traces the progression of treatments, from gemcitabine and carboplatin prior to 2017 to the introduction of two checkpoint inhibitors, atezolizumab and pembrolizumab, in 2017. However, she notes the shift back to platinu...

Results of Cohort K of the EV-103 Trial EV Monotherapy or in Combination With Pembro in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer - Guru...

Details
Alicia Morgans and Guru Sonpavde discuss the results of Cohort K of the EV-103 trial presented at the 2022 European Society for Medical Oncology (ESMO) Annual Congress. There remains a critical need for effective and tolerable first-line treatment options in locally advanced or metastatic urothelial cancer. In second and later-line settings, both EV and pembrolizumab have independently shown an ov...

Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg

Details
Jonathan Rosenberg joins Alicia Morgans to discuss long-term outcomes of enfortumab vedotin (EV) in patients with previously treated advanced urothelial carcinoma (UC) in the EV-301 trial. The EV-301 trial demonstrated improvements in progression-free and overall survival for patients with previously treated advanced UC who received EV compared to chemotherapy. In discussing how this updated analy...

EV-201 Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zach Klaassen delve into the EV-201 study. This phase 2 trial investigates the efficacy of enfortumab vedotin in treating cisplatin-ineligible patients with advanced urothelial carcinoma who have previously received PD-1 or PD-L1 inhibitors. The study, conducted across 59 sites in North America, Europe, and Asia, shows a promising objective response rate of 52%, with 20% of...

EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonat...

Details
Jonathan Rosenberg discusses the promising results from Cohort K, a part of a multi-cohort phase 1B/2 study examining enfortumab in combination with other agents, notably pembrolizumab. The primary endpoint, objective response rate, indicates a 64.5% response with the combination treatment. This rate is significant compared to a 45% response observed with enfortumab monotherapy. Dr. Rosenberg also...

Molecular Subtyping and Neoadjuvant Chemotherapy in Bladder Cancer - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.” This study is investigating how molecular subtypes impact pathological response and survival in patients receiving preoperative cisplatin-based chemotherapy. This study shows that tumor classification by gene expression profiling and...

Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a Lancet Oncology publication on the KEYNOTE-361 trial, pembrolizumab alone, or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma: A randomized open-label phase three trial. The authors of this trial assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemothe...

CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the CheckMate 274 publication, “Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.” The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. The authors of this publication assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery t...

The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta

Details
In this conversation, Arlene Siefker-Radtke and Shilpa Gupta join Patrick Hensley to discuss the role of risk-stratified neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer who are undergoing radical cystectomy. Drs. Siefker-Radtke and Gupta explain how systemic chemotherapy can be very challenging for bladder cancer patients due to the long-term side effects it can cause, alo...

ATLANTIS Trial Explores Precision Medicine in Urothelial Carcinoma - Robert Jones

Details
Alicia Morgans speaks with Robert Jones about the ATLANTIS Trial, focusing on an embedded randomization that studied the efficacy of Cabozantinib in urothelial carcinoma patients post-chemotherapy. Dr. Jones explains that the ATLANTIS platform aims to explore precision medicine in urothelial cancer and includes an "all-comers" arm to ensure broader patient participation. Unfortunately, the study f...